Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.
Where this comes from
- Record sourced from PubMed, PMID 42489991.
- Also identified by DOI 10.1245/s10434-026-20016-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biochemical recurrence (BCR) is a common clinical event after radical prostatectomy (RP). Accurate risk stratification and timely individualized treatment are still major problems in clinical practice and research. Current clinical guidelines and key original studies describe several main components of BCR management after RP, including how BCR is defined, which factors affect prognosis, how imaging is used for evaluation, and which treatment options are available. These components help guide clinical decisions at different stages of care. Recent work has focused on the use of artificial intelligence (AI). Multimodal AI models that integrate clinical features, MRI-based radiomics, and whole-slide image pathology features demonstrate superior performance compared with single-modal approaches in predicting BCR after RP.